- Home
- PSHG vs CVM Comparison
PSHG vs CVM Comparison
Compare PSHG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | CVM |
|---|---|---|
| Founded | 2010 | 1983 |
| Country | Greece | United States |
| Employees | N/A | 44 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 21.4M |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PSHG | CVM |
|---|---|---|
| Price | $1.73 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.0K | ★ 805.5K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $49.57 | N/A |
| Revenue Next Year | $2.73 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.58 | $0.89 |
| 52 Week High | $2.58 | $13.48 |
Technical Indicators
Market Signals| Indicator | PSHG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 37.27 |
| Support Level | $1.71 | $0.89 |
| Resistance Level | $2.09 | $1.86 |
| Average True Range (ATR) | 0.05 | 0.21 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 50.00 | 65.69 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.